Gillmore Staging System for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
The Gillmore staging system stratifies ATTR‑CM prognosis using serum NT‑proBNP and estimated glomerular filtration rate.
Indicazioni d'uso
Used to stage confirmed ATTR‑CM into prognostic groups with NT‑proBNP and eGFR to estimate survival and guide timing of therapy and referral. Applicable to both ATTRwt and ATTRv. Stage I (NT‑proBNP ≤3000 ng/L, eGFR ≥45 mL/min), II (intermediate), III (NT‑proBNP >3000 ng/L and eGFR <45 mL/min) stratifies mortality risk (HR 2.05–3.80 vs stage I) 1 [Level II evidence].
Approfondimenti e precauzioni
Stratifies prognosis using NT‑proBNP ≤/ >3000 ng/L and eGFR ≥/ <45 mL/min, predicting median survival of ~69, 47, and 24 months for stages I–III respectively 1 [Level I evidence]. Use cautiously because survival estimates predate modern therapies, may underestimate risk in advanced HF or cardiorenal syndrome, and should not guide therapy eligibility alone per ACC consensus 2 [Level III evidence].